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Abstract
Background: Ewing sarcoma and desmoplastic small round cell tumors (DSRCT) are rare and
clinically aggressive sarcomas usually characterized by oncogenic fusion proteins involving EWS.
Emerging studies of Ewing sarcoma have demonstrated EWS-FLI1-driven chromatin remodeling
as a key aspect of tumorigenicity. In particular, the lysine-specific demethylase KDM1A/LSD1 is
linked to transcriptional regulation of target genes orchestrated by the EWS portion of the fusion
protein interactingwith repressive chromatin-remodeling complexes. Consistent with this model,
depletion of KDM1A supports it is a molecular therapeutic target in Ewing sarcoma cells, but
effective drugs need to be identified.
Procedure: A comprehensive phenotypic analysis of the effects of catalytic KDM1A inhibitors
ORY-1001 and GSK2879552, including clinically relevant doses, was carried out in 2D and 3D
spheroid models of Ewing sarcoma andDSRCT.
Results:Catalytic inhibition of KDM1Adid not affect cell viability in 2D and 3D assays and had no
impact on invasion in a 3D assay.
Conclusions: Overall, evidence presented here does not support inhibition of KDM1A catalytic
demethylase activity as an effective therapeutic strategy for Ewing sarcoma or DSRCT. However,
roles of KDM1A beyond its demethylase activity should be considered for these sarcomas.
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1 INTRODUCTION
Ewing sarcoma is a rare and highly aggressive sarcoma affecting chil-
dren and young adults. Recent developments in our understanding
of the molecular mechanisms underlying this disease have not yet
translated into significant improvements in patients’ outcomes, and
treatment has remained unchanged.1
Ewing sarcoma is characterized by chromosomal rearrangements
between the gene EWSR1 and genemembers of the ETS-domain family
Abbreviations: 3D, three-dimensional; AML, acutemyeloid leukemia; ANOVA, analysis of variance; CHD, chromodomain; DSRCT, desmoplastic small round cell tumor; EWSR1, EWSRNA binding
protein 1; EZH2, enhancer of zeste homolog 2; FLI1, friend leukemia integration 1; H3K4, histone 3 lysine 4; HDAC, histone deacetylase; KDM1A (LSD1), lysine-specific demethylase; MTA1,
metastasis-associated protein; MTS, 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; NuRD, nucleosome remodeling deacetylase complex; PVDF,
polyvinylidene fluoride; SCLC, small cell lung cancer; SDS, sodium dodecyl sulfate; ULA, ultra-low attachment;WT1,Wilms tumor.
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of transcription factors; approximately 85% to 90% of Ewing sarcoma
tumors exhibit FLI1 as the EWSR1 fusion partner.2 Additional EWSR1
chromosomal translocations exist, such as fusion with WT1, found in
95% of cases of desmoplastic small round cell tumor (DSRCT).3,4
EWS-FLI1 has been identified as the main driver of Ewing sarcoma
tumorigenicity through unique pioneer properties that increase
genome-wide chromatin accessibility at GGAA microsatellite
repeats.5–7 This is achieved through histone-modifying enzymes
and chromatin-remodeling complexes changing the epigenetic status
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TABLE 1 KDM1A inhibitors
Compound ORY-1001 GSK2879552 GSK-LSD1 SP2509
Structure




















Phase I studies in SCLC
(NCT02034123) and AML
(NCT02177812) have been
terminated because the risk
benefit does not favor
continuation. Phase I/II study
inMDS (NCT02929498)
NA NA
of genomic regions and creating de novo enhancer elements that
establish the Ewing sarcoma transcriptional signature.8–10 In par-
ticular, the nucleosome remodeling deacetylase complex (NuRD;
also known as Mi-2), a multi-subunit chromatin-remodeling complex
commonly associated with repression of transcriptional activity,
was identified to be relevant in the silencing of EWS-FLI1 target
genes.10,11 Essentially, the catalytic activity in the NuRD com-
plex involves deacetylation by histone deacetylase 2 (HDAC2) and
3 (HDAC3), coupled with demethylation by lysine-specific demethy-
lase 1 (KDM1A; also referred to as LSD1, AOF2, and BHC110).9,10
The working model proposed by Sankar et al consists of EWS-
FLI1 binding to promoters of repressed target genes, followed by the
recruitment of the NuRD complex through interaction between its
subunits chromodomain 4 (CHD4) and metastasis-associated protein
1 (MTA1) and the EWS portion of the fusion protein. Following treat-
mentwith SP2509, a tool compound targetingKDM1A, the EWS-FLI1-
driven transcriptional signature of both upregulated and downregu-
lated genes was reversed.10 Inhibition of KDM1A with SP2509 also
resulted in apoptosis and disruption of the oncogenic phenotype.10
KDM1A is a well-characterized histone lysine demethylase
belonging to the family of flavin-dependent amine oxidases that
has an important role in stem cell maintenance through transcrip-
tional repression.12–14 This demethylase is also overexpressed
in Ewing sarcoma and other sarcomas including DSRCT and
rhabdomyosarcoma.15–17 Moreover, the key role of the EWS portion
of the fusion protein in the interaction with repressive chromatin-
remodeling complexes makes inclusion of DSRCT, possessing the
EWS-WT1 fusion, relevant to study alongside EWS-FLI1 in Ewing
sarcoma.8,9
Currently, the KDM1A inhibitor ORY-1001 is being investigated
in the clinic in adult patients with acute myeloid leukemia (AML) and
small cell lung cancer (SCLC). In addition, a trial with GSK2879552
has recently been stopped citing that the benefits do not outweigh
the risk in relapsed refractory SCLC18–21 (Table 1). These compounds
are potent irreversible inhibitors of KDM1A, which covalently modify
the FAD cofactor of this demethylase to inhibit catalytic activity.22,23
However, their use as a therapeutic strategy for Ewing sarcoma has
not been comprehensively assessed. Given the rationale for target-
ing KDM1A in Ewing sarcoma, in this work, we sought to test the
potential for repurposing these clinical candidates against KDM1A as
a novel treatment for these sarcomas.
The current report investigates the effect of catalytic inhibitors of
KDM1A on cell viability in 2D and 3Dmodels, and invasion using a 3D
spheroid assay. Importantly, we show that clinically available inhibitors
of KDM1A catalytic demethylase activity, despite having an effect on
viability at a low nanomolar range against leukemia cell lines, do not
have an effect in preclinical models of Ewing sarcoma and DSRCT.
Therefore, catalytic inhibition of KDM1A should not be considered as
a therapeutic strategy for Ewing sarcoma.
2 METHODS
2.1 Cell lines
Ewing sarcoma cell lines A673 and TC71 were kindly provided by
Dr. Enrique de Álava (IBiS, Spain). The desmoplastic small round cell
tumor cell line JN-DSRCT-124 was obtained from Sean B. Lee, and
leukemia cell lines MV(4;11) and MOLT-4 were obtained from DSMZ,
Germany. Cell lines used were cultured in the appropriate media sup-
plemented with 10% fetal bovine serum (Gibco, Thermo Fisher Sci-
entific, UK), 1% penicillin–streptomycin (Gibco), and 1% GlutaMAX
(Gibco) in a humidified incubator at 37◦Cand5%CO2. Standard proce-
dures were utilized for maintenance, freezing, and thawing. Cells were
Mycoplasma-free tested with the PlasmoTest Mycoplasma Detection
Kit (InvivoGen, UK) according to instructions. Cell lines were authenti-
catedwith short tandem repeat testing using theGenePrint 10 system
(Promega, UK).
2.2 Reagents and drug treatments
The followingKDM1A inhibitorswere used:ORY-1001,GSK2879552,
GSK-LSD1, and SP2509 (Table 1; SelleckChem, UK). Stocks (10 mM)
ROMO-MORALES ET AL. 3 of 9
were prepared in H2O for ORY-1001 and GSK2879552, and in DMSO
for GSK-LSD1 and SP2509 and stored at−80◦C.
2.3 Cell viability assays
A673 cells were seeded at 2000 cells/well, TC71 cells at 4000
cells/well, and JN-DSRCT-1 at 4000 cells/well in 96-well plates for via-
bility assays (six replicates for each condition). Viability was assessed
by an MTS (3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt) assay using the CellTiter 96
AqueousOne Solution Cell Proliferation Assay (Promega).Mediawere
replaced with 100 𝜇L of Opti-MEM and 20 𝜇L of CellTiter 96 Aque-
ous One Solution Cell Proliferation Assay. Plates were incubated
for two hours in normal culturing conditions prior to measuring the
absorbance of eachwell at 492 nm.
For MV(4;11) and MOLT-4 viability assays, cells were seeded at
100 000/well (6-well plate) and cultured for the indicated time. Viable
cell counts were determined by Trypan blue assay (Sigma-Aldrich, UK).
2.4 3D spheroid culture
Three-dimensional spheroids were generated and cultured using the
GravityTRAP ULA Plate 96-well (PerkinElmer, UK) unless otherwise
indicated. Prior to seeding, wells were pre-wet with 40 𝜇L of medium.
One thousand cells in 70 𝜇L were seeded into each well. Plates were
spun for two minutes at 250 RCF to remove trapped air bubbles. Rou-
tinemediumchangeswere performedevery48hours by carefully aspi-
rating the medium from the ledge at the inside wall of the well and
replenishing it with freshmedium.
2.5 Image analysis of 3D spheroids
Digital images of spheroids were captured throughout the duration of
the experiments using an IN Cell Analyzer 2200 imaging system (GE
Healthcare Life Sciences, UK), and the surface areawas assessed at the
focal planewithmaximumdiameterwith INCell Investigator INDevel-
oper Toolbox (GEHealthcare Life Sciences).
2.6 Western blot analysis
2.6.1 H3K4me2 immunoblot
Following treatment, 2.5 × 105 cells were lysed with 50 𝜇L of 3×
Laemmli buffer made up with 2 mL of 1 M Tris Base pH 6.8, 3 mL of
100%Glycerol, 8mL of 10% SDS, 300 𝜇L of 1% bromophenol blue, and
400 𝜇L of 𝛽-mercaptoethanol (freshly added at the time of whole-cell
lysate preparation).
Standard protein extraction with cell lysis buffer (Cell Signaling
Technology, UK) and Western blot analysis techniques were used for
remaining Western blots. Five to 30 micrograms of protein extract or
5 𝜇L of whole-cell lysate in 3X Laemmli buffer was loaded into wells of
a NuPAGE 4% to 12% Bis-Tris protein gels (Invitrogen, Thermo Fisher
Scientific, UK). Protein gels were transferred onto PVDF membranes
with iBlot2 transfer stacks on the iBlot2 transfer system (Invitrogen)
following the manufacturer’s instructions. The iBlot2 transfer system
was run at 20 V for sevenminutes.
Densitometry values for each band were normalized to total pro-
tein or housekeeping control of the control sample band and relative
to the indicated control. Western blots are representative of at least
two independent repeats.
2.7 3D invasion assay
A673 and TC71 cells were seeded at a density of 500 cells per well
in ultra-low attachment (ULA) round-bottom 96-well plates (Corn-
ing, UK). After three days of culturing, spheroids were treated with
KDM1A inhibitors at the indicated concentration for 10 days. Fifty
microliters of medium was removed from each well and replaced with
50 𝜇L of fresh mediumwith drug every 48 hours. Following treatment,
50 𝜇L of medium was removed and carefully replaced with 50 𝜇L of
Matrigel (Corning) containing drug, achieving a final concentration of
Matrigel of 4.5 mg/mL. Plates were then incubated at 37◦C and 5%
CO2 in an IncuCyte Zoom (Sartorius, UK) for 48 hours where images
were taken every hour tomonitor invasion.
2.8 qRT-PCR
RNA was extracted with TRIzol according to the manufacturer’s
protocol.25 A673 cell line cDNA was synthesized using the High
Capacity cDNA Reverse Transcriptase kit (Applied Biosystems,
CA, USA) following the manufacturer’s instructions. Multiplex PCR
reactions were set up in triplicate in 384-well optical-reaction PRC
plates (Applied Biosystems) and run on a ViiA 7 Real-Time PCR
System (Applied Biosystems, CA, USA). The following TaqMan probes
were used: LOX Hs00942480_m1, TGFBR2 Hs00234253_m1,
HMOX1 Hs01110250_m1, E2F1 Hs00153451_m1, and CAV1
Hs00971716_m1. Human RPLPO endogenous control (Applied
Biosystems, CA, USA) was used to normalize gene expression.
2.9 Statistical analysis
GraphPadPRISM7andR studio3.3.2wereused to carry out the statis-
tical analyses. Error bars represent means ± standard deviation from
various independent experiments as indicated in figure legends. Sta-
tistical significance was measured by one-way ANOVA with post hoc
Sidak test formultiple comparisons and two-wayANOVAwithpost hoc
Dunnett test and Sidak testwhere applicable.P < 0.05was considered
significant and indicated by *, P < 0.01 is indicated by **, P < 0.001 is
indicated by ***, and P < 0.0001 is indicated by ****.
3 RESULTS
Presently, there is noevidencedemonstratingwhether the clinical drug
candidates for KDM1Ahave activity in preclinicalmodels of Ewing sar-
coma. To begin to address this question, Ewing sarcoma cell lines A673
and TC71 were treated with compounds for 96 hours to investigate
the effect of KDM1A inhibition on cell viability. The cell lines tested
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showed no sensitivity to treatment with the irreversible inhibitors
of KDM1A demethylase function: ORY-1001 and GSK2879552
(Figure 1). Conversely, treatment with tool compound SP2509
revealed a rapid decrease in viability with GI50s in the submicromo-
lar range (A673: 123 nM and TC71: 355 nM). Morphological assess-
ment of cells following treatmentwith clinical drug candidates showed
no differences between treated and untreated. Cell morphology in the
SP2509-treated cells was consistent with apoptosis (Figure S1A).9,10
These effects were replicated in theDSRCT cell line, only showing sen-
sitivity to SP2509 and not to the clinical drug candidates (Figure S1B).
To address the discrepancy between theKDM1A inhibitors, a chemical
probe validated as a potent and selective inhibitor of KDM1A catalytic
demethylase activity (GSK-LSD1) was also tested in these sarcoma
cell lines (http://www.thesgc.org/chemical-probes/LSD1).23,26 Again,
treatment had no meaningful effect on cell viability, with only a
50% reduction at 10 𝜇M in one cell line (TC71; Figure 1; Support-
ing Information Figure S1C). KDM1A protein levels were unaffected
following treatment with clinical drug candidates ORY-1001 and
GSK2879552 after 48, 72, 96, and 168 hours (Supporting Information
Figure S1D–S1E).
Importantly, consistent with their in vitro inhibition of KDM1A
demethylase activity, all four compounds were able to modulate
KDM1A-mediated demethylation of the H3K4 methyl mark, a well-
characterized KDM1A substrate.15 Following 72 hours of treatment
with 2 𝜇M for all drugs, including the tool compound GSK-LSD1, there
was an increase in the global levels ofH3K4me2 in bothEwing sarcoma
cell lines (Figure 1 and 1D). Furthermore, to investigate the impact on
EWS-FLI1-driven transcription, we selected downstream target genes
of the fusion protein and assessed by qRT-PCR following treatment
with ORY-1001 and GSK2879552. Extended exposure of up to two
weeks (336 hours) was conducted to ensure prolonged catalytic inhi-
bition. We did not observe a biologically relevant change in expres-
sion of five target genes at a range of time points following treat-
ment with ORY-1001 and GSK2879552 at 2 and 10 𝜇M, despite sta-
tistical significance (Figure 1F). As a positive control, treatment with
tool compound SP2509 (250 nM) reversed expression of LOX and
HMOX1 in agreement with previous reports, but not TGFBR2 or EWS-
FLI1 activated genes E2F1 and CAV1 (Supporting Information Figure
S1F–S1H),9,10 possibly due to the lower concentration used in our
experiments.
To further demonstrate compound activity, we assessed the
response of leukemia cells, previously shown to be sensitive to inhi-
bition of KDM1A catalytic function by ORY-1001 in the nanomolar
range.22 In agreement with published findings, the clinical candidate
ORY-1001, as well as chemical probe GSK-LSD1, showed a reduction
in cell viability upon treatment with compound at 10 nM concentra-
tions in two leukemia cell lines (Supporting Information Figure S2Aand
S2B). The clinical candidate GSK2879552 also decreased cell viability
at 2 𝜇M (Supporting Information Figure S2C).
To perform a more comprehensive evaluation of the effect of
KDM1A inhibition, assessment of cell viability experiments was
expanded to 3Dmodels of Ewing sarcoma. Three-dimensional cell cul-
ture systemshavebecomemoreprominent in preclinical studies due to
their ability tomore closely represent tissue compartments and enable
longer experimental time frames.27 Tumor spheroids, for example, can
recapitulate aspects of the tumor microenvironment that ultimately
influence drug response.28 A673 spheroid cultures were treated with
ORY-1001 and SP2509 for 10 days with a dose range between 0.3 and
10 𝜇M (Figure 2 and 2B). Again, no effect on growth was observed
with the irreversible inhibitor of KDM1Acatalytic functionORY-1001,
whereas SP2509was active, albeit at higher concentrations compared
with 2D cultures (Figure 2 and 2B). Drugs targeting epigenetic mod-
ifying enzymes often require prolonged inhibition for maximal drug
potency and response to treatment.22,23,29 We therefore additionally
treated spheroids for up to 21 days with a maximum concentration
of 100 𝜇M of both clinical candidates (ORY-1001 and GSK2879552).
Both clinical candidates had no effect upon spheroid growth (Figure 2
and 2E), even in the extended assay.
Finally, KDM1A has been reported to have a role in migration and
invasion.30 To complete the phenotypic assessment of KDM1A inhi-
bition, we evaluated if Ewing sarcoma cells showed a change in their
invasive phenotype upon inhibition of KDM1A catalytic demethylase
activity. A673 and TC71 spheroids were pretreated for 10 days with
theKDM1A inhibitors, and subsequently cultured in aMatrigelmatrix,
in which invasion was monitored for a further 48 hours. A compari-
son of the total spheroid area indicated that KDM1A inhibition had no
impact on the invaded area (Figure 3 and 3B; Supporting Information
Figure S3). Consistent with our previous results, the measured
spheroid area was not affected in the 10-day pretreatment with either
2 𝜇M or 10 𝜇M concentrations of compound (Figure 3; Supporting
Information Figure S3). Again, we included the chemical probe GSK-
LSD1 in the assay; it also had no effect on invasion (Figure 3 and 3B;
Supporting Information Figure S3).
4 DISCUSSION
The Ewing sarcoma gene-expression profile heavily relies on EWS-
FLI1 coordinating vast epigenetic rewiring through the recruitment
and activity of chromatin-remodeling complexes.7,8,31 In this context,
KDM1A, an active subunit of the NuRD complex, has been reported
to have an important role in repressing and activating target genes
of the fusion protein EWS-FLI1.9,10 The functional role of KDM1A
in Ewing sarcoma oncogenesis, alongside high expression in this and
other sarcomas such as DSRCT, has made it a promising therapeu-
tic target.32,33 In light of this, our aim was to assess the therapeutic
potential ofKDM1A inhibitors (ORY-1001andGSK2879552) in Ewing
sarcomamodels.
Global or promoter-specific accumulation of methylation of H3K4
is not always seen followingKDM1A inhibition regardless of decreased
KDM1A activity.23,34 However, in our findings, the global change in
H3K4me2 upon treatment with all KDM1A inhibitors demonstrated
capacity to effectively inhibit KDM1A catalytic activity. Importantly,
this did not translate into reversal of expression of EWS-FLI1 down-
stream target genes by ORY-1001 and GSK2879552 analyzed by
qRT-PCR.
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F IGURE 1 Effects of KDM1A inhibition on Ewing sarcoma cell lines. (A–B) Ewing sarcoma cell lines A673 and TC71were exposed to a range of
concentrations of KDM1A inhibitors for 96 hours. Cell viability was assessed byMTS assay. Means± SD of 6 replicates; graphs are representative
of three independent repeats. (C–D)Western blot of H3K4me2 of A673 and TC71 cell lines treated with KDM1A inhibitors (SP2509, ORY-1001,
GSK2879552, and GSK-LSD1) (2 𝜇M) and their respective vehicle controls. Densitometry values shown above each blot were normalized to total
H3 and relative to each vehicle control.Western blots are representative of at least two independent repeats. (E–F) Effect of KDM1A inhibitors
on EWS-FLI1 target genes expression. qRT-PCR analysis of LOX andHMOX1 in A673 cells treated with vehicle or KDM1A inhibitors ORY-1001
(2 𝜇M, 10 𝜇M), GSK2879552 (2 𝜇M, 10 𝜇M), and SP2509 (250 nM). Normalized fold changewas adjusted to human RPLPO endogenous control.
Means± SD of three replicates. Data are representative of two independent repeats. Statistical analysis: two-way ANOVAwith Dunnett and
Sidakmultiple comparisons test, not significant comparisons are not shown; * P< 0.05; ** P< 0.01; *** P< 0.001; **** P< 0.0001
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F IGURE 2 Effect of KDM1A inhibitors on the cell proliferation of Ewing sarcoma spheroids. Growth curve of A673 spheroids treated with a
range of concentrations of KDM1A inhibitors ORY-1001 (A) and SP2509 (B) for 10 days. (C)Wells containing representative spheroids at day 10
of treatment with ORY-1001 and SP2509 at 10 𝜇M, 3 𝜇M, and vehicle, respectively. Scale bars: 100 𝜇m. Long-term treatment of A673 spheroids
with clinical candidates ORY-1001 (D) and GSK2879552 (E) for 21 days. Maximum area at greater width of a sphere wasmeasured in images
taken over the different time courses. Means± SD of 6–10 replicates
Catalytic inhibition of KDM1A with the clinical drug candidates
ORY-1001 and GSK2879552 reproduced the reported decrease in
cell viability in leukemia cell lines.22 On the other hand, repurpos-
ing of these clinical compounds for Ewing sarcoma did not exhibit
anticancer activity in 2D and 3D viability assays even at concentra-
tions up to 100 𝜇M. A validated potent and selective chemical probe
for inhibition of KDM1A catalytic function (http://www.thesgc.org/
chemical-probes/LSD1),23,26 which shares the same chemical scaffold
with the clinical candidate compounds and has the same mechanism
of action through irreversible covalent modification of the FAD cofac-
tor, also had no effect on the cell viability of Ewing sarcoma cells in 2D
and 3D. Prolonged inhibition, as a means to achieve maximal efficacy,
as in reports with inhibitors of Enhancer of Zeste Homolg 2 (EZH2) in
lymphoma, did not alter the response to these inhibitors of KDM1A
catalytic function.22,23,29
KDM1A’s reported role in modulating self-renewal and differentia-
tion in embryonic stem cells also encompasses regulation of migration
during normal mammalian development.14,35 Importantly, in solid
tumors, high levels of KDM1A have been associated with metastasis,
and inhibition of this demethylase has been shown to attenuate
migration and invasion in breast cancer cell lines.30 Metastasis is
a key problem in Ewing sarcoma with patients with disseminated
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F IGURE 3 Effects of KDM1A inhibitors on the invasion of Ewing sarcoma spheroids. (A) Three-dimensional spheroid invasion assay with
Ewing sarcoma cell lines A673 spheroids pretreated with KDM1A clinical drug candidates: ORY-1001 andGSK2879552 and tool compound
GSK-LSD1 for 10 days (2 𝜇M). (B) A673 and TC71 total spheroid areameasured with IncuCyte ZOOM software for 48 hours (10-day
pretreatment with 2 𝜇M).Means± SD of 3–5 replicates; graphs are representative of two independent repeats. Statistical analysis: two-way
ANOVA andDunnett multiple comparison test, P< 0.05 between drugs tested within the same time point
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disease showing dismal survival below30%.36 Therefore, investigating
invasion as part of the phenotypic assessment of KDM1A inhibition
was highly relevant. However, in our 3D invasion assay, KDM1A
inhibition did not alter the invasive phenotype, and it particularly
failed to suppress invasion in Ewing sarcoma spheroids.
The disease context and the nature of the role that KDM1A plays in
various malignancies are key determinants of KDM1A inhibition as a
therapeutic strategy. In leukemia, KDM1Ademethylase activity acts as
a key silencer of regulators of hematopoiesis, essential in maintaining
leukemia stem cells.37 This transcriptional repression and differentia-
tion arrest can be relieved through inhibition ofKDM1Acatalytic func-
tion or protein knockdown.22,37 However, in the context of Ewing sar-
coma, despite the observed change in the methylation levels of H3K4,
inhibition of KDM1A catalytic function was insufficient to modulate
a selection of known target genes of EWS-FLI and impair Ewing sar-
coma cells survival. This suggests catalytic activity of KDM1Amay not
contribute to establishing EWS-FLI1’s transcriptional program. Recent
findings showed that shRNA-mediated depletion of KDM1A in Ewing
sarcoma cells resulted in severe growth impairment and cell death,
confirming their dependency on this demethylase.38 The discrepancy
between our results through inhibition of KDM1A catalytic function
and knockdown of the multidomain protein strongly suggests a non-
canonical role forKDM1A, independent from its demethylase function.
These characteristics coincide with other epigenetic regulators such
as EZH2. Its emerging methyltransferase- and polycomb-independent
roles provide novel therapeutic potential for inhibitors disrupting its
docking capacity.39
In line with this model, recent reports in prostate cancer cell lines
described a scaffolding role for KDM1A,whereby catalytically inactive
KDM1A was still able to establish the prostate cancer gene network
and ensure survival of castration-resistant prostate cancer cell lines.40
This was further confirmedwith the tool compound SP2509, proposed
as an allosteric inhibitor binding to the H3 pocket region of KDM1A,
capable of inducing cell death in prostate cancer cell lines. Similarly,
this could also explain the previously observed reversal of the EWS-
FL1 signature effects with SP2509 in Ewing sarcoma cells.10 How-
ever, it is noteworthy that SP2509 has been shown to effectively cause
cell death regardless of KDM1A expression in a leukemia KDM1A
knockout cell line and its isogenic control.41 In addition to disrupting
KDM1A’s complex formation capabilities, SP2509may have additional
cytotoxic effects independent from KDM1A binding. Consistent with
this, 2-hydroxyphenyl-hydrazone structural motif within SP2509 has
previously been identified as a pan-assay interference flag and has the
potential to elicit promiscuous biological activity.42–44 KDM1A’s role
as a docking element for additional proteins may play a more promi-
nent part in Ewing sarcoma cells survival than previously considered.15
Our work is particularly timely and pertinent as a drug of the same
mechanistic class of KDM1A inhibitors as the irreversible KDM1A
demethylase inhibitors tested here has entered phase I trials in Ewing
sarcoma patients (NCT03514407). In summary, we demonstrate that
the clinical candidates ORY-1001 and GSK2879552, which act pre-
dominantly as inhibitors ofKDM1Acatalytic function, are not effective
against in vitro models of Ewing sarcoma. The data presented here do
not support clinical trials exploring inhibition of KDM1A demethylase
function as a therapeutic strategy for the treatment of Ewing sarcoma
andDSRCT.
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